Abstract 2058: Augmenting the My Cancer Genome knowledge resource with data from AACR Project GENIE
Authors: Micheel Christine M. , LeNoue-Newton Michele L. , Holt Marilyn E. , Jain Neha , Levy Mia A. 
Published: September 2020

Abstract
My Cancer Genome (https://www.mycancergenome.org; MCG) recently released a major update to the website, with an ultimate goal of adding of AACR Project GENIE data to demonstrate frequency of genetic variants in cancer, estimate matching to clinical trial arms, and augment the case report database. This abstract presents use of GENIE data 1) as part of a new process to automatically select cancer types and biomarkers for inclusion and 2) to display prevalence data on the website. My Cancer Genome is a publicly available precision cancer medicine knowledgebase managed by the Vanderbilt-Ingram Cancer Center. The mission of MCG is to curate and disseminate knowledge regarding the clinical significance of genomic alterations in cancer. The website was first made available to the public in early 2011 and has since grown into a resource visited more than 7,000 times a week by people from well over 200 countries and territories around the world. The new website was released in June 2019, and it includes several new features: a new clinical trials search using manually curated disease and biomarker eligibility criteria, therapeutic assertions illustrating situations where having or not having a particular biomarker detected supports or does not support use of a particular drug, and the inclusion of data from AACR Project GENIE. Addition of GENIE data to MCG was approved by AACR Project GENIE's Data Use and Publications Committee. First, any disease or biomarker associated with a therapeutic assertion or clinical trial has a page on MCG. In addition, any disease or biomarker that appears five times or more in the GENIE dataset is also given a page. In this way, the website will remain up-to-date with almost all diseases and biomarkers that can be considered relevant as precision oncology knowledge and GENIE grow. Next, GENIE data appears on disease and biomarker pages, in both charts and descriptive text. On disease pages, such as the breast carcinoma page, GENIE data appear in a chart of most commonly altered genes in breast carcinoma and most common alterations in breast carcinoma; in addition, text describing the prevalence of mutations appears under each gene listed in the section on significant genes in breast carcinoma. On biomarker pages, such as the ABL1 page, GENIE data appear in a chart of the most common diseases where ABL1 has been found to be altered and the most common alterations in ABL1 that appear in GENIE cases; in addition, text describing the prevalence of ABL1 mutations appears under each disease listed in the section on the significance of ABL1 in diseases. The addition of data from AACR Project GENIE to My Cancer Genome has improved and enhanced MCG's content, ability to scale, and ability to maintain. Finally, inclusion of data from AACR Project GENIE on My Cancer Genome provides a simple way to select and view subsets of GENIE data for specific diseases and biomarkers in the context of relevant precision oncology therapies and clinical trials.
Citation Format: Christine M. Micheel, Michele L. LeNoue-Newton, Marilyn E. Holt, Neha Jain, Mia A. Levy. Augmenting the My Cancer Genome knowledge resource with data from AACR Project GENIE [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 2058.